HDAC6 and B-cell chronic lymphocytic leukemia: This study therefore highlights an integral role for HDAC inhibitors in combination with immunotherapeutic agents and provides rationale to test selective HDAC6 inhibitors in combination with immune checkpoint blocking antibodies in CLL patients.